Pharmacokinetics and safety of a modified-release psilocybin formulation: A SAD Phase I trial in normal-weight and overweight/obese participants

Paper. Signor A, Comai S, Pasut G et al.. British Journal of Clinical Pharmacology, 21 Sep 2026.

Tags: Human, Psilocybin.

Weekly Science Digest, 19 Sep 2026 to 25 Sep 2026, finding 5: In brief

phase 1 SAD of a modified-release psilocybin (REL-P11) at 0.5-2 mg aimed at sub-perceptual metabolic dosing, in normal-weight and obese adults

Read the original

—
Node—
Statuslive
Throughput—